Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/30636
Title: Effect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with chronic myeloid leukemia treated with imatinib
Authors: Labachevski, Bojan
Zendelovska, Dragica 
Petrushevska, Marija 
Popova Labachevska, Marija
Pivkova Veljanovska, Aleksandra 
Labachevska Gjatovska, Liljana 
Ridova, Nevenka 
Trajkova, Sanja 
Panovska Stavridis, Irina 
Balkanov, Trajan 
Keywords: Oxidative stress
d-ROM
PAT
OSI
chronic myeloid leukemia
imatinib
Aronia melanocarpa
Issue Date: Mar-2024
Publisher: Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
Journal: Macedonian Pharmaceutical Bulletin
Abstract: Antioxidant status in patients with chronic myeloid leukemia (CML) is significantly decreased in comparison with healthy individuals. Oxidative stress (OS) may be associated with the pathophysiology of CML and can influence on development of resistance to imatinib. The aim of our study was to investigate the effect of Aronia melanocarpa extract (A-lixir 400 PROTECT®) on OS in CML patients treated with imatinib. In this study a total of 40 CML patients treated with imatinib for longer than 1 month were included: twenty patients were treated with imatinib and A-Lixir 400 PROTECT® (treatment group) and twenty patients were treated only with imatinib (control group). OS parameters (d-ROM, PAT and OSI) were measured at the initial visit, and after 21 and 42 days of treatment. Adjuvant treatment with A-Lixir 400 PROTECT® could lead to attenuation of OS. d-ROM and OSI in this group of patients were significantly higher at initial visit when compared to values after 21 and 42 days of treatment (p<0.05). Total antioxidant capacity (PAT) was significantly higher after 21 and 42 days of treatment initiation in comparison with the pretreatment values. In the control group no significant differences were obtained between investigated parameters at any time of measurement. We can conclude that adjuvant treatment with A-Lixir 400 PROTECT® after 21 and 42 days lead to significant reduction of OS in patients with CML treated with imatinib.
URI: http://hdl.handle.net/20.500.12188/30636
DOI: 10.33320/maced.pharm.bull.2023.69.02.002
Appears in Collections:Faculty of Medicine: Journal Articles

Files in This Item:
File Description SizeFormat 
Бојан Лабачевски 2023.pdfEffect of standardized Aronia Melanocarpa extract on oxidative stress and antioxidant status in patient with chronic myeloid leukemia treated with imatinib308.93 kBAdobe PDFView/Open
Show full item record

Page view(s)

21
checked on Jul 13, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.